Brimonidine is neuroprotective against glutamate-induced neurotoxicity, oxidative stress, and hypoxia in purified rat retinal ganglion cells

Kelvin Yoon Chiang Lee,1,2 Mao Nakayama,1 Makoto Aihara,1 Yi-Ning Chen,1 Makoto Araie1

1Department of Ophthalmology, University of Tokyo, Graduate School of Medicine, Tokyo, Japan; 2Singapore National Eye Centre, Singapore

Purpose: To investigate the neuroprotective effect of α2-adrenergic agonist brimonidine in the presence of glutamate-induced neurotoxicity, oxidative stress, and hypoxia on in vitro cultures of purified rat retinal ganglion cells (RGCs).

Methods: Purified RGC cultures were obtained from retinas of 6–8-day old Wistar rats, following a two-step immunopanning procedure. After 72 h of cultivation, the neuroprotective effect of brimonidine (0.01 μM, 0.1 μM, and 1 μM) was investigated by culturing the RGCs under glutamate, oxidative, and hypoxic stress for a further 72 h, 24 h, and 12 h, respectively. Glutamate neurotoxicity was induced by adding glutamate (25 μM), while oxidative stress was induced by substituting the culture medium with B27 supplement without antioxidants, and hypoxia was induced by cultivation in a controlled-atmosphere incubator with oxygen levels 5% of the normal partial pressure. The RGC viability under each stress condition normalized to that under normal condition was evaluated as live cell percentage based on a total of 7–8 full repeated experiments.

Results: The cell survival percentages of cultures exposed to glutamate, oxidative, and hypoxic stress were 58.2%, 59.3%, and 53.2%, respectively. Brimonidine dose dependently increased RGC survival in the presence of glutamate (80.6% at 1 μM), oxidative (79.8% at 1 μM), and hypoxic (72.3 and 77.4% at 0.1 and 1 μM, respectively) stress. In the presence of α2-adrenergic antagonist yohimbine (10 μM), brimonidine (1 μM) showed no protective effects on RGC viability.

Conclusions: At a concentration of 0.1 μM or higher, brimonidine increased survival of purified rat RGCs in the presence of glutamate neurotoxicity, oxidative stress, and hypoxia. The neuroprotective effect of brimonidine is mediated via α2-adrenergic receptors at the RGC level.

Glaucoma is the second leading cause of blindness in the world, and various mechanisms of glaucomatous optic neuropathy (GON) have been thought to cause retinal ganglion cell (RGC) death leading to visual loss [1]. Elevated intraocular pressure (IOP), ischemia, elevated glutamate levels, excessive production of nitric oxide and free radical generation, oxidative stress and deprivation of neurotrophic factors can trigger the apoptotic mechanisms in RGCs, and a combination of these factors would lead to RGC apoptosis in glaucoma [2–8]. Hence, an ideal neuroprotective drug should be able to target the multiple apoptotic pathways triggered by these factors.

Brimonidine is a highly selective α2-adrenergic receptor agonist [9]. Brimonidine lowers IOP by reducing aqueous humor production and also by stimulating aqueous humor outflow through the uveoscleral pathway [10]; it is an IOP-lowering drug that is widely used to manage glaucoma patients [11–13]. Brimonidine has also been found to have a neuroprotective effect beyond IOP lowering. Animal models of optic nerve injury, ocular hypertension, and retinal ischemia have been used to demonstrate the neuroprotective effect of brimonidine [4,14–17]. However, in these in vivo studies where drugs were applied either topically or systemically, it was difficult to determine if the observed effects were attributable to direct effects on RGCs or indirect remote effects of the drug on inflammatory mediators, local blood supply, or other ocular tissues.

Because of the wide use and importance of brimonidine as an antiglaucoma drug and its potential in retarding the progression of glaucomatous visual field damage of open angle glaucoma patients through action beyond IOP reduction [18], further characterization of the neuroprotective effect of brimonidine has been assessed, particularly at the level of the RGC. In vitro studies with purified rat RGC cultures have been previously used to determine the neuroprotective effects of β-adrenergic antagonists and calcium channel blockers in various stresses, including hypoxic and oxidative stress [19–21]. Hypoxia has been reported to induce release of glutamate from isolated retina or cultured retinal cells as well as to activate the caspase cascade leading to RGC apoptosis [22–25]. Hypoxia-induced RGC death in the in vitro purified RGC model has been suggested to be mostly independent of excitotoxicity through glutamate receptors [19]. In vivo,
however, glutamate levels may be increased from release by other neuronal and/or glial cells or dysfunction of glutamate uptake by glial cells [26]. The retina and its neurons consuming high oxygen and exposed to high levels of light are prone to oxidative stress, which leads to an increase in reactive oxygen species and possibly cell damage from influx of Ca²⁺ [2,27-30].

The aim of our study is to examine the neuroprotective effect of brimonidine against glutamate-induced neurotoxicity, oxidative stress, and hypoxia, using purified rat RGC cultures.

METHODS

Materials: All animal studies were in compliance with the Association for Research in Vision and Ophthalmology (ARVO) Resolution on the Use of Animals in Research. Poly-L-lysine, BSA (BSA), L-glutamine, human recombinant brain-derived neurotrophic factor (BDNF), rat recombinant ciliary neurotrophic factor (CNTF), and yohimbine hydrochloride (Y-3125) were obtained from Sigma (St. Louis, MO). The papain dissociation system was from Worthington Biochemical (Lakewood, NJ); mouse anti-IRP (CD172a) monoclonal antibody (MAB 1407P), and mouse anti-IRP and mouse Thy1.1 monoclonal antibody (MAB 1406) were obtained from Chemicon International (Temecula, CA). The live/dead viability cytotoxicity kit (L-3224) was obtained from Molecular Probes (Eugene, OR). Brimonidine tartrate was obtained from Allergan, Inc. (Irvine, CA). B27 supplement minus antioxidants (AO-), which induced oxidative stress [33,34]. These were then cultivated for a further 72 h.

Oxidative stress: Control coverslips were moved to freshly prepared neurobasal medium with B27 supplement normally containing potent antioxidants (reduced glutathione, vitamin E, vitamin E acetate, catalase, and superoxide dismutase), while coverslips for oxidative treatment were transferred to neurobasal medium containing B27 without these five antioxidants (AO-), which induced oxidative stress [33,34]. The RGCs were further cultivated for 24 h.

Hypoxic stress: Control coverslips were moved to freshly prepared neurobasal medium with B27 supplement and placed in normoxic conditions, while hypoxic stress was induced by placing the cultures in a hypoxic environment (controlled atmosphere of 5% O₂, 5% CO₂, 90% N₂ at 37 °C) for 12 h.

Application of brimonidine: Seven repeated full experiments were performed using three concentrations (0.01 μM, 0.1 μM, and 1 μM) of brimonidine; these were added separately to each of the test cultures.

Effect of brimonidine in the presence of yohimbine: We studied the effect of yohimbine (10 μM), a specific α₂-adrenergic receptor antagonist on the neuroprotective effect of brimonidine (1 μM) by adding brimonidine alone, brimonidine with yohimbine, and yohimbine alone to RGCs cultured under glutamate neurotoxicity, oxidative stress, and hypoxia. Eight separate, repeated, full experiments were performed with yohimbine.

Assay of retinal ganglion cell survival rate: At the end of cultivation, the surviving RGCs were processed for viability by labeling with calcein-AM (2 μM), a component of the live/dead viability/cytotoxicity kit [32]. Live RGCs were defined as having a calcein-stained cell body with neurites extending at least 3 cell diameters from the cellular body. The RGC viability was calculated from two wells, those with exposure to the insults and the control group. The RGCs were counted manually in a total of eight fields of standardized location at 10× magnification. Live RGCs in each well were expressed as a cell survival percentage of the control culture with control medium. The average cell survival percentage of seven to
eight experiments for each condition was expressed as the mean±standard deviation (SD).

Statistical analysis: Dunnett’s test was used to determine if test groups were significantly different from controls. A p value of <0.05 was considered significant.

RESULTS

Neuroprotection against glutamate neurotoxicity: After completing 72 h of cultivation in the presence of glutamate alone, 58.2±12.5% of the RGCs survived compared to controls (Figure 1A). In the presence of 0.01 μM, 0.1 μM, and 1.0 μM of brimonidine, RGC survival was 56.8±11%, 64.5±11%, and 80.6±7.7%, respectively (n=7, p=0.990, 0.564, and 0.002, respectively).

In the yohimbine experiments, the neuroprotective effect of brimonidine at 1.0 μM against glutamate neurotoxicity was replicated (p<0.001). RGC survival in the presence of brimonidine and yohimbine and of yohimbine alone was 51.9±7.4% and 58.2±7.7%, respectively (Figure 2A); these were not statistically different from controls with only glutamate (p=1.00 and 0.220).

Neuroprotection against oxidative stress: In the presence of oxidative stress (AO-), RGC survival was reduced to 59.3±4.1% compared to the AO+ control group in normal cultivating conditions (Figure 1B). In the brimonidine AO-group, RGC survival was 61.8±7.1%, 68.3±6.2%, and 79.8±4.7% for brimonidine concentrations of 0.01 μM,
0.1 μM, and 1.0 μM, respectively (n=7, p=0.845, 0.064, and <0.001, respectively).

In the yohimbine experiments, the neuroprotective effect of 1.0 μM brimonidine against oxidative stress was replicated (p<0.001, Figure 2B). In the AO- group with brimonidine and yohimbine, 37.8±5.1% of RGCs survived, which was not significantly different from the AO- control group (p=0.215). Yohimbine alone did not significantly alter RGC survival (38.4±4.1%) compared to AO- controls in conditions of oxidative stress (p=0.342).

Neuroprotection against hypoxia: Under hypoxic conditions (Figure 1C), RGC survival was reduced to 52.4±6.2% compared to the control group (Figure 1C). In the brimonidine group, RGC survival was 57.6±5.9%, 72.3±9.9%, and 77.4±7.7% for brimonidine concentrations of 0.01 μM, 0.1 μM, and 1.0 μM, respectively (n=7, p=0.762, 0.004, and <0.001, respectively).

In the yohimbine experiments, the neuroprotective effect of brimonidine against hypoxia was replicated (p<0.001, Figure 2C). In the presence of yohimbine, the RGC survival was not significantly increased by brimonidine (p=0.926). Yohimbine alone had no significant effect on RGC survival under hypoxic conditions (p=0.963).

**DISCUSSION**

We have demonstrated using an in vitro model of purified rat RGC culture that brimonidine is neuroprotective at the level of the RGC. The neuroprotective effect of brimonidine was present in three different stress situations—glutamate induced neurotoxicity, oxidative stress, and hypoxic stress. Brimonidine, at a 1 μM concentration, significantly increased RGC viability under all three stresses; these stresses have been implicated in the development of GON [2-5,8,14,16,17, 35-37].

Baptiste et al. [15] used mixed retinal cell cultures of neurons and glia to demonstrate the neuroprotective effect of α2-adrenergic agonist UK14304 against glutamate-induced neurotoxicity. We believe our work is the first to report the neuroprotective effect of brimonidine on RGCs against glutamate-induced neurotoxicity, oxidative stress, and hypoxic stress, using purified rat RGC cultures. Our in vitro model of a purified rat RGC culture further adds to the evidence that brimonidine has neuroprotective effects not related to the lowering of IOP [4,14-17].

The neuroprotective pathways triggered by brimonidine were effectively blocked by the selective α2-adrenergic antagonist yohimbine. Previously, α2-adrenergic antagonists, like rauwolscine and yohimbine, were shown to reverse the neuroprotective effects of α2-adrenergic agonists in models of optic nerve injury and photoreceptor light-induced damage [17,38,39]. Mixed retinal cell culture experiments showed that brimonidine reduced glutamate-induced Ca2+ increases in retinal neurons in culture, the effect of which was reversed by yohimbine [40]. Our in vitro experiments with purified RGCs demonstrated that the neuroprotective effect of brimonidine is at the RGC level via α2-adrenergic receptors.

Our results showed a similar percentage protection effect over three different concentrations of brimonidine and under three different stresses. It is possible that a final common pathway of the three neurotoxic insults may be countered by the effect of brimonidine on α2-adrenergic receptors. The α2-adrenergic receptors are expressed in the inner plexiform and RGC layers of the retina in various mammalian species, such as rats and humans [41-45]. Activation of α2-adrenergic receptors may protect RGCs from experimental injury by preventing abnormal elevation of cytosolic free Ca2+ through modulation of the L-type Ca2+ channel or glutamate receptor activity [15,40,46]. In these studies, over 0.3 μM of brimonidine was needed to reduce cytosolic Ca2+ through the L-type Ca2+ channel, whereas over 3 μM of brimonidine was required for the modulation of glutamate-induced Ca2+ increase. Thus, the mechanism of neuroprotection observed in our study may be partly attributed to L-type Ca2+ channel modification because the effect was observed at a brimonidine concentration of 1 μM.

Under our culture conditions, hypoxia mainly induced glutamate-independent apoptosis [19]. Anti-apoptotic pathways of α2-adrenergic receptor activation also include increased endogenous BDNF expression in RGCs, upregulation of basic fibroblast growth factor (bFGF), and induction of the anti-apoptotic genes bcl-2 and bcl-xl [47-49]. Thus, the neuroprotective effect of brimonidine on hypoxia-induced RGC death may be attributed to these mechanisms.

In contrast to glutamate- or hypoxia-induced neurotoxicity, oxidative stress induced by using B27 without antioxidative agents in the current model mainly induced necrosis by activation of the calpain/catepsin pathway [21]. The mechanism of brimonidine’s effect on the calpain/ catepsin pathway deserves future study.

Pharmacologically, brimonidine can activate the α2-adrenergic receptor at a concentration of 2 nM or higher. Studies with monkeys showed that the vitreous humor brimonidine concentration was 82 nM after topical application of 0.2% brimonidine [50]. In humans, topically applied 0.2% brimonidine tartrate and 0.15% brimonidine purite twice or three times daily resulted in acquired vitreous levels of 185 nM and 19 nM brimonidine, respectively [51, 52]. Thus, a topical or systemic application of brimonidine may be enough to activate α2-adrenergic receptors not only to reduce IOP but also to induce neuroprotective effects at the level of RGCs.

In summary, we first found that brimonidine acting via the α2-adrenergic receptor was neuroprotective on purified rat RGCs exposed to glutamate-induced neurotoxicity, oxidative stress, or hypoxic stress at concentrations of 10−7 M or higher.
In an attempt to search for effective treatment of GON beyond IOP-lowering therapy, the potential of brimonidine or other α-2-selective adrenergic agonists to be able to affect not only the glutamate-induced apoptosis pathway but also the glutamate-independent necrotic or calpain/catepsin-dependent necrotic pathway in RGCs may merit further study.

ACKNOWLEDGMENTS

Supported in part by grants H18-Kankakukiippan-001 from the Ministry of Education, Culture, Sports, Science and Technology of Japan (M.A.).

REFERENCES

1. Resnikoff S, Pascolini D, Ytay'a'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82:844-51. [PMID: 15640920]

2. Castagne V, Gautschi M, Lefevre K, Posada A, Clarke PG. Relationships between neuronal death and the cellular redox status. Focus on the developing nervous system. Prog Neurobiol 1999;59:397-423. [PMID: 10501635]

3. Flammer J, Pache M, Resink T, Clarke PG. The glutamate-induced apoptosis pathway but also the α-2-selective adrenergic agonists to be able to affect not only the glutamate-independent necrotic or calpain/catepsin-dependent necrotic pathway in RGCs may merit further study.

4. Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci 2000; 41:4169-74. [PMID: 11095611]

5. Lipton SA. Retinal ganglion cells, glaucoma and neuroprotection. Prog Brain Res 2001; 131:712-8. [PMID: 11420983]

6. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res 1999; 18:39-57. [PMID: 9920498]

7. Seki M, Lipton SA. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma. Prog Brain Res 2008; 173:495-510. [PMID: 18929130]

8. Wax MB, Tezel G. Neurobiology of glaucomatous optic neuropathy: diverse cellular events in neurodegeneration and neuroprotection. Mol Neurobiol 2002; 26:45-55. [PMID: 12392055]

9. Cantor LB, Burke J. Brimonidine. Expert Opin Investig Drugs 1997; 6:1063-83. [PMID: 15989664]

10. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995; 113:1514-7. [PMID: 7487618]

11. Wilensky JT. The role of brimonidine in the treatment of open-angle glaucoma. Surv Ophthalmol 1996; 41:S3-7. [PMID: 8970244]

12. Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998; 12:225-41. [PMID: 9534022]

13. David R. Brimonidine (Alphagan): a clinical profile four years after launch. Eur J Ophthalmol 2001; 11:S72-7. [PMID: 11592536]

14. Ahmed FA, Hegazy K, Chaudhary P, Sharma SC. Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Res 2001; 913:133-9. [PMID: 11549376]

15. Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Chauhan BC, Tremblay F, Kelly MEM. Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retina. Invest Ophthalmol Vis Sci 2002; 43:2666-76. [PMID: 12147601]

16. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001; 42:2849-55. [PMID: 11687528]

17. Yoles E, Wheeler LA, Schwartz M. Alpha2-adrenergic receptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 1999; 40:65-73. [PMID: 9888428]

18. Krupin T, Liebmam JM, Greenfield DS, Rosenberg LF, Ritch R, Yang JW. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology 2005; 112:376-85. [PMID: 15745762]

19. Chen YN, Yamada H, Mao W, Matsuyama S, Aihara M, Araie M. Hypoxia-induced retinal ganglion cell death and the neuroprotective effects of beta-adrenergic antagonists. Brain Res 2007; 1148:28-37. [PMID: 17368577]

20. Yamada H, Chen YN, Aihara M, Araie M. Neuroprotective effect of calcium channel blocker against retinal ganglion cell damage under hypoxia. Brain Res 2006; 1071:75-80. [PMID: 16413513]

21. Yu ZK, Chen YN, Aihara M, Mao W, Uchida S, Araie M. Effects of beta-adrenergic receptor antagonists on oxidative stress in purified rat retinal ganglion cells. Mol Vis 2007; 13:833-9. [PMID: 17615544]

22. Neal MJ, Cunningham JR, Hutson PH, Hogg J. Effects of ischaemia on neurotransmitter release from the isolated retina. J Neurochem 1994; 62:1025-33. [PMID: 7906713]

23. Ohia SE, Awe OS, Opere CA, Leonard AM, Harris LC, Sharif NA. Hypoxia-induced [(3)H]D-aspartate release from isolated bovine retina: modulation by calcium-channel blockers and glutamatergic agonists and antagonists. Curr Eye Res 2001; 23:386-92. [PMID: 11910529]

24. Rego AC, Santos MS, Oliveira CR. Oxidative stress, hypoxia, and ischemia-like conditions increase the release of endogenous amino acids by distinct mechanisms in cultured retinal cells. J Neurochem 1996; 66:2506-16. [PMID: 8632176]

25. Tezel G, Wax MB. Inhibition of caspase activity in retinal cell apoptosis induced by various stimuli in vitro. Invest Ophthalmol Vis Sci 1999; 40:2660-7. [PMID: 10509663]

26. Vorwerk CK, Naskar R, Schuettauf F, Quinto K, Zurakowski D, Gochenhauer G, Robinson MB, Macker SA, Dreyer EB. Depression of retinal glutamate transporter function leads to elevated intravitreal glutamate levels and ganglion cell death. Invest Ophthalmol Vis Sci 2000; 41:3615-21. [PMID: 11060260]

27. Choi DW. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci 1988; 11:465-9. [PMID: 2469166]

© 2010 Molecular Vision
28. Organisciak DT, Darrow RM, Barsalou L, Darrow RA, Kutty RK, Kutty G, Wiggert B. Light history and age-related changes in retinal light damage. Invest Ophthalmol Vis Sci 1998; 39:1107-16. [PMID: 9620069]

29. Orrenius S, Burkitt MJ, Kass GE, Dypbukt JM, Nicotera P. Calcium ions and oxidative cell injury. Ann Neurol 1992; 32:S33-42. [PMID: 1510379]

30. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis 1999; 5:32. [PMID: 10562656]

31. Kawasaki A, Otori Y, Barnstable CJ. Muller cell protection of rat retinal ganglion cells from glutamate and nitric oxide neurotoxicity. Invest Ophthalmol Vis Sci 2000; 41:3444-50. [PMID: 11006237]

32. Otori Y, Wei JY, Barnstable CJ. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest Ophthalmol Vis Sci 1998; 39:972-81. [PMID: 9579476]

33. Brewer GJ, Torricelli JR, Evege EK, Price PJ. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res 1993; 35:567-76. [PMID: 8377226]

34. Perry SW, Norman JP, Litzburg A, Gelbard HA. Antioxidants are required during the early critical period, but not later, for neuronal survival. J Neurosci Res 2004; 78:485-92. [PMID: 15389829]

35. Chung HS, Harris A, Evans DW, Kagemann L, Garzozi HJ, Martin B. Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv Ophthalmol 1999; 43:S43-50. [PMID: 10416746]

36. Costa VP, Harris A, Stefansson E, Flammer J, Kriegstein GK, Orzalesi N, Heijl A, Renard JP, Serra LM. The effects of antiglaucoma and systemic medications on ocular blood flow. Prog Retin Eye Res 2003; 22:769-805. [PMID: 14575724]

37. Flammer J. The vascular concept of glaucoma. Surv Ophthalmol 1994; 38:S3-6. [PMID: 7940146]

38. Wen R, Cheng T, Li Y, Cao W, Steinberg RH. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 1996; 16:5986-92. [PMID: 8815881]

39. Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW. Alpha(2)-Adrenergic agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther 2001; 296:216-23. [PMID: 11123383]

40. Dong CJ, Guo Y, Wheeler L, Hare WA. Alpha2 adrenergic receptor-mediated modulation of cytosolic Ca++ signals at the inner plexiform layer of the rat retina. Invest Ophthalmol Vis Sci 2007; 48:1410-5. [PMID: 17325190]

41. Zarin MA, Wamsley JK, Palacios JM, Kuhar MJ. Autoradiographic localization of high affinity GABA, benzodiazepine, dopaminergic, adrenergic and muscarinic cholinergic receptors in the rat, monkey and human retina. Brain Res 1986; 374:75-92. [PMID: 3013364]

42. Wheeler LA, Woldemussie E. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. Eur J Ophthalmol 2001; 11:S30-5. [PMID: 11592528]

43. Kalapesi FB, Coroneo MT, Hill MA. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br J Ophthalmol 2005; 89:758-63. [PMID: 15923515]

44. Matsuo T, Cynader MS. Localization of alpha-2 adrenergic receptors in the human eye. Ophthalmic Res 1992; 24:213-9. [PMID: 1359487]

45. Woldemussie E, Wijono M, Pow D. Localization of alpha 2 receptors in ocular tissues. Vis Neurosci 2007; 24:745-56. [PMID: 17986363]

46. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci 2008; 49:4515-22. [PMID: 18566471]

47. Wheeler LA, Lai R, Woldemussie E. From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol 1999; 9:S17-21. [PMID: 10230601]

48. Tatton WG, Chalmers-Redman RM, Tatton NA. Apoptosis and anti-apoptosis signalling in glaucomatous retinopathy. Eur J Ophthalmol 2001; 11:S12-22. [PMID: 11592526]

49. Gao H, Qiao X, Cantor LB. WuDunn D. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol 2002; 120:797-803. [PMID: 12049866]

50. Acheampong AA, Shackleton M, John B, Burke J, Wheeler L, Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab Dispos 2002; 30:421-9. [PMID: 11901096]

51. Kent AR, Nussdorf JD, David R, Tyson F, Small D, Fellows D. Vitreous concentration of topically applied brimonidine-purite 0.15%. J Ocul Pharmacol Ther 2006; 22:242-6. [PMID: 16910864]